ALK, ROS1, and RET - Does the Partner Gene Matter?

被引：0
|
作者：
Lovly, Christine [1 ]
Childress, Merrida [1 ]
机构：
[1] Vanderbilt Univ, Sch Med, Div Hematol Oncol, Dept Med, Nashville, TN 37212 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
RET; ros1; NTRK1; ALK;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MS22.02
引用
收藏
页码：S128 / S129
页数：2
相关论文
共 50 条
  • [21] Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer
    Rogers, Toni-Maree
    Russell, Prudence A.
    Wright, Gavin
    Wainer, Zoe
    Pang, Jia-Min
    Henricksen, Leigh A.
    Singh, Shalini
    Stanislaw, Stacey
    Grille, James
    Roberts, Esteban
    Solomon, Benjamin
    Fox, Stephen B.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 611 - 618
  • [22] Immunoexpression of BAP1, ROS1, and ALK in Spitzoid Melanocytic Tumors
    Cardili, Leonardo
    Viana, Cristiano Ribeiro
    Germano, Andressa
    Fernandes, Mariana
    Barcellos, Denise
    Landman, Gilles
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2018, 26 (06) : 514 - 520
  • [23] Different ALK/ROS1 Variants in Prognosis of Surgical NSCLC Patients
    Zhao, Chao
    Li, Xuefei
    Su, Chuanxia
    Ren, Shengxiang
    Chen, Xiaoxia
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1508 - S1509
  • [24] Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
    Collier, T. Lee
    Maresca, Kevin P.
    Normandin, Marc D.
    Richardson, Paul
    McCarthy, Timothy J.
    Liang, Steven H.
    Waterhouse, Rikki N.
    Vasdev, Neil
    MOLECULAR IMAGING, 2017, 16 : 1 - 3
  • [25] New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)
    Alessandro Russo
    Ana Rita Lopes
    Michael G. McCusker
    Sandra Gimenez Garrigues
    Giuseppina R. Ricciardi
    Katherine E. Arensmeyer
    Katherine A. Scilla
    Ranee Mehra
    Christian Rolfo
    Current Oncology Reports, 2020, 22
  • [26] Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
    Drilon, Alexander
    Ou, Sai-Hong Ignatius
    Cho, Byoung Chul
    Kim, Dong-Wan
    Lees, Jeeyun
    Lin, Jessica J.
    Zhu, Viola W.
    Ahns, Myung-Ju
    Camidge, D. Ross
    Nguyen, Judy
    Zhai, Dayong
    Deng, Wei
    Huang, Zhongdong
    Rogers, Evan
    Liu, Juliet
    Whitten, Jeff
    Lim, John K.
    Stopatschinskaja, Shanna
    Hyman, David M.
    Doebele, Robert C.
    Cui, J. Jean
    Shaw, Alice T.
    CANCER DISCOVERY, 2018, 8 (10) : 1227 - 1236
  • [27] A Mass Spectrometry Assay to Simultaneously Analyze ROS1 and RET Fusion Gene Expression in Non-Small-Cell Lung Cancer
    Wijesinghe, Priyanga
    Bepler, Gerold
    Bollig-Fischer, Aliccia
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 381 - 386
  • [28] Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
    Aguado, C.
    Teixido, C.
    Gimenez-Capitan, A.
    Marin, E.
    Perez-Rosado, A.
    Cabrera, C.
    Roman, R.
    Moya, I.
    Viteri, S.
    Rosell, R.
    Molina-Vila, M. A.
    Reguart, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S380 - S380
  • [29] ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?
    Nichetti, Federico
    Lo Russo, Giuseppe
    Prelaj, Arsela
    Provenzano, Leonardo
    de Braud, Filippo
    Cabiddu, Mary
    Garassino, Marina Chiara
    Petrelli, Fausto
    THROMBOSIS RESEARCH, 2020, 194 : 176 - 177
  • [30] ROS1 gene rearrangement and clinicopathological characteristics in Chinese NSCLC patients
    Ke, Wenbo
    Xu, Zhigao
    Xue, Liquan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (05): : 5594 - 5599
12345